# ACT-GLOBAL IA Thrombolysis(ACT-REACT-004)Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632

> **NCT07687056** · PHASE3 · NOT_YET_RECRUITING · sponsor: **University of Calgary** · enrollment: 1500 (estimated)

## Conditions studied

- Stroke, Acute Ischemic
- Endovascular Thrombectomy
- Acute Ischemic Stroke AIS

## Interventions

- **BIOLOGICAL:** Tenecteplase or Alteplase- depending upon availability at each treating centre
- **OTHER:** Control

## Key facts

- **NCT ID:** NCT07687056
- **Lead sponsor:** University of Calgary
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-10
- **Primary completion:** 2030-12-31
- **Final completion:** 2031-03-31
- **Target enrollment:** 1500 (ESTIMATED)
- **Last updated:** 2026-07-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07687056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07687056, "ACT-GLOBAL IA Thrombolysis(ACT-REACT-004)Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07687056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*